These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 2848467)

  • 21. Outer Membrane Interaction Kinetics of New Polymyxin B Analogs in Gram-Negative Bacilli.
    Akhoundsadegh N; Belanger CR; Hancock REW
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing use of colistin and polymyxin B in the critically ill.
    Nation RL; Li J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of polymyxin B sulfate and polymyxin B nonapeptide on growth and permeability of the yeast Saccharomyces cerevisiae.
    Boguslawski G
    Mol Gen Genet; 1985; 199(3):401-5. PubMed ID: 2993791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
    Sader HS; Rhomberg PR; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):379-81. PubMed ID: 26415906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cooperative action of SP-A and its trimeric recombinant fragment with polymyxins against Gram-negative respiratory bacteria.
    Coya JM; Fraile-Ágreda V; de Tapia L; García-Fojeda B; Sáenz A; Bengoechea JA; Kronqvist N; Johansson J; Casals C
    Front Immunol; 2022; 13():927017. PubMed ID: 36159837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
    Vaara M; Sader HS; Rhomberg PR; Jones RN; Vaara T
    J Antimicrob Chemother; 2013 Mar; 68(3):636-9. PubMed ID: 23134658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The susceptibility of enteropathogenic and non-enteropathogenic porcine Escherichia coli strains to polymyxins and other antibiotics.
    Larsen JL; Søgaard H
    Nord Vet Med; 1981; 33(9-11):393-402. PubMed ID: 6276857
    [No Abstract]   [Full Text] [Related]  

  • 29. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
    Alipour M; Halwani M; Omri A; Suntres ZE
    Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of polymyxin B nonapeptide on Aeromonas salmonicida.
    McCashion RN; Lynch WH
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1414-9. PubMed ID: 2823698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of the synergistic activity of neomycin-polymyxin B association against pathogens responsible for otitis externa.
    Tempera G; Mangiafico A; Genovese C; Giudice E; Mastrojeni S; Nicolosi D; Ferneri PM
    Int J Immunopathol Pharmacol; 2009; 22(2):299-302. PubMed ID: 19505383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of susceptibility testing methods for polymyxin.
    Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC
    Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B.
    Cornelissen F; Van den Bossche H
    Chemotherapy; 1983; 29(6):419-27. PubMed ID: 6317296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC; Reis AO; Jones RN
    J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
    Tsubery H; Ofek I; Cohen S; Fridkin M
    J Med Chem; 2000 Aug; 43(16):3085-92. PubMed ID: 10956216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.
    Draper LA; Cotter PD; Hill C; Ross RP
    BMC Microbiol; 2013 Sep; 13():212. PubMed ID: 24069959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
    Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
    ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
    Gales AC; Jones RN; Sader HS
    J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells.
    Brunati C; Thomsen TT; Gaspari E; Maffioli S; Sosio M; Jabes D; Løbner-Olesen A; Donadio S
    J Antimicrob Chemother; 2018 Feb; 73(2):414-424. PubMed ID: 29092042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.